. .
Français
France
Livres similaires
Autres livres qui pourraient ressembler au livre recherché:
Outils de recherche
s'inscrire

Connectez-vous avec Facebook:

S'inscrire
Mot de passe oublié?


Historique de recherche
Liste pense-bête
Liens vers eurolivre.fr

Partager ce livre sur…
Livre conseillé
Actualités
Conseils d'eurolivre.fr
Publicité
Annonce payée
FILTRE
- 0 Résultats
prix le plus bas: 229,95 €, prix le plus élevé: 243,80 €, prix moyen: 235,12 €
Checkpoint Controls and Targets in Cancer Therapy - Humana Press
Livre non disponible
(*)
Humana Press:

Checkpoint Controls and Targets in Cancer Therapy - nouveau livre

ISBN: 9781617796357

ID: 9c8997734985a007dd7ad0f5feed5b20

Checkpoint regulation is critical in understanding cancer development and cancer therapy. This book builds upon existing concepts of checkpoints and aims to expand our understanding of the inner workings of the critical checkpoint machinery. Much work over the last two decades has firmly established that loss of cell cycle checkpoint regulation, and resultant unabated cellular proliferation, is an inherent characteristic of cancer. This loss may occur through aberration in any single component involved in signal transduction pathways that orchestrate checkpoint regulation, which may manifest through either a failure to activate the checkpoint or a failure to respond to the activated checkpoint. In normal cells, checkpoint pathways are activated when genetic or cellular homeostasis is compromised, and signals are then transduced to re-stabilize homeostasis, and, failing this, to activate the apoptotic machinery to induce a cellular suicidal response. This implies that both survival and cell death pathways are induced following checkpoint activation, and that the final decision is dependant on the net result of integrating the two sets of signals.It is intriguing that checkpoint pathways are also critical in cancer therapy to provide an apoptotic stimulus when cellular damage induced by the therapeutic agent is detected by the sensor system. Therefore, it is not surprising that failure in pro-survival checkpoint response will render tumor cells hypersensitive to cytotoxics and, conversely, failure in pro-apoptotic checkpoint response will induce genetic instability and/or therapeutic resistance. Understanding the intricacies of checkpoint response is, therefore, central to the design of therapeutic regimen that will enhance antitumor effects. Although early versions of this design entail combination of cytotoxic agents with cell cycle or checkpoint inhibitors, a greater understanding of the concepts could make such combinations clinically more effective. The contributions in this book will consolidate the current state of knowledge on checkpoint responses that may lay the foundation for hypothesis-driven rational approaches in advancing the management of cancer. The immediate attraction of the book to the scientific community is that it represents a timely opportunity to build upon existing concepts of checkpoints to expand our understanding of the inner workings of the critical checkpoint machinery. The present understanding has provided ample appreciation that response to checkpoint activation is manifested through coordinated inhibition of cyclin-dependent kinase (CDK) complexes in G1, S and/or the G2 phase in order to arrest the cell cycle. Kinase inhibition can occur through several mechanisms, including inhibitory phosphorylation of CDK, destruction of the cognate cyclins, and recruitment of CDK inhibitors from the INK and WAF1/CIP1 families. However, the wealth of information from recent discoveries needs to be examined critically to consolidate our conceptual knowledge of checkpoints. At the same time, there is acute awareness in the diversity of checkpoint response between cytotoxic agents, and this serves as a reminder of the magnitude of complexity that is inherent in checkpoint regulation. This volume is intended to bring the cancer research community closer toward an improved understanding of this regulation, how checkpoint abnormalities can impact negatively on cancer therapy, and emerging strategies to target checkpoint response as a therapeutic end-point. Bücher / Fremdsprachige Bücher / Englische Bücher 978-1-61779-635-7, Humana Press

Nouveaux livres Buch.de
Nr. 30710177 Frais d'envoiBücher und alle Bestellungen die ein Buch enthalten sind versandkostenfrei, sonstige Bestellungen innerhalb Deutschland EUR 3,-, ab EUR 20,- kostenlos, Bürobedarf EUR 4,50, kostenlos ab EUR 45,-, Versandfertig in 5 - 7 Tagen, zzgl. Versandkosten, Livraison non-comprise
Details...
(*) Livre non disponible signifie que le livre est actuellement pas disponible à l'une des plates-formes associées nous recherche.
Checkpoint Controls and Targets in Cancer Therapy - Humana Press
Livre non disponible
(*)

Humana Press:

Checkpoint Controls and Targets in Cancer Therapy - nouveau livre

ISBN: 9781617796357

ID: 112855015

Much work over the last two decades has firmly established that loss of cell cycle checkpoint regulation, and resultant unabated cellular proliferation, is an inherent characteristic of cancer. This loss may occur through aberration in any single component involved in signal transduction pathways that orchestrate checkpoint regulation, which may manifest through either a failure to activate the checkpoint or a failure to respond to the activated checkpoint. In normal cells, checkpoint pathways are activated when genetic or cellular homeostasis is compromised, and signals are then transduced to re-stabilize homeostasis, and, failing this, to activate the apoptotic machinery to induce a cellular suicidal response. This implies that both survival and cell death pathways are induced following checkpoint activation, and that the final decision is dependant on the net result of integrating the two sets of signals. It is intriguing that checkpoint pathways are also critical in cancer therapy to provide an apoptotic stimulus when cellular damage induced by the therapeutic agent is detected by the sensor system. Therefore, it is not surprising that failure in pro-survival checkpoint response will render tumor cells hypersensitive to cytotoxics and, conversely, failure in pro-apoptotic checkpoint response will induce genetic instability and/or therapeutic resistance. Understanding the intricacies of checkpoint response is, therefore, central to the design of therapeutic regimen that will enhance antitumor effects. Although early versions of this design entail combination of cytotoxic agents with cell cycle or checkpoint inhibitors, a greater understanding of the concepts could make such combinations clinically more effective. The contributions in this book will consolidate the current state of knowledge on checkpoint responses that may lay the foundation for hypothesis-driven rational approaches in advancing the management of cancer. The immediate attraction of the book to the scientific community is that it represents a timely opportunity to build upon existing concepts of checkpoints to expand our understanding of the inner workings of the critical checkpoint machinery. The present understanding has provided ample appreciation that response to checkpoint activation is manifested through coordinated inhibition of cyclin-dependent kinase (CDK) complexes in G1, S and/or the G2 phase in order to arrest the cell cycle. Kinase inhibition can occur through several mechanisms, including inhibitory phosphorylation of CDK, destruction of the cognate cyclins, and recruitment of CDK inhibitors from the INK and WAF1/CIP1 families. However, the wealth of information from recent discoveries needs to be examined critically to consolidate our conceptual knowledge of checkpoints. At the same time, there is acute awareness in the diversity of checkpoint response between cytotoxic agents, and this serves as a reminder of the magnitude of complexity that is inherent in checkpoint regulation. This volume is intended to bring the cancer research community closer toward an improved understanding of this regulation, how checkpoint abnormalities can impact negatively on cancer therapy, and emerging strategies to target checkpoint response as a therapeutic end-point. Checkpoint regulation is critical in understanding cancer development and cancer therapy. This book builds upon existing concepts of checkpoints and aims to expand our understanding of the inner workings of the critical checkpoint machinery. Buch (fremdspr.) Bücher>Fremdsprachige Bücher>Englische Bücher, Humana Press

Nouveaux livres Thalia.de
No. 30710177 Frais d'envoi, Versandfertig in 2 - 3 Tagen, DE (EUR 0.00)
Details...
(*) Livre non disponible signifie que le livre est actuellement pas disponible à l'une des plates-formes associées nous recherche.
Checkpoint Controls and Targets in Cancer Therapy - Humana Press
Livre non disponible
(*)
Humana Press:
Checkpoint Controls and Targets in Cancer Therapy - nouveau livre

ISBN: 9781617796357

ID: 116234361

Much work over the last two decades has firmly established that loss of cell cycle checkpoint regulation, and resultant unabated cellular proliferation, is an inherent characteristic of cancer. This loss may occur through aberration in any single component involved in signal transduction pathways that orchestrate checkpoint regulation, which may manifest through either a failure to activate the checkpoint or a failure to respond to the activated checkpoint. In normal cells, checkpoint pathways are activated when genetic or cellular homeostasis is compromised, and signals are then transduced to re-stabilize homeostasis, and, failing this, to activate the apoptotic machinery to induce a cellular suicidal response. This implies that both survival and cell death pathways are induced following checkpoint activation, and that the final decision is dependant on the net result of integrating the two sets of signals.It is intriguing that checkpoint pathways are also critical in cancer therapy to provide an apoptotic stimulus when cellular damage induced by the therapeutic agent is detected by the sensor system. Therefore, it is not surprising that failure in pro-survival checkpoint response will render tumor cells hypersensitive to cytotoxics and, conversely, failure in pro-apoptotic checkpoint response will induce genetic instability and/or therapeutic resistance. Understanding the intricacies of checkpoint response is, therefore, central to the design of therapeutic regimen that will enhance antitumor effects. Although early versions of this design entail combination of cytotoxic agents with cell cycle or checkpoint inhibitors, a greater understanding of the concepts could make such combinations clinically more effective. The contributions in this book will consolidate the current state of knowledge on checkpoint responses that may lay the foundation for hypothesis-driven rational approaches in advancing the management of cancer. The immediate attraction of the book to the scientific community is that it represents a timely opportunity to build upon existing concepts of checkpoints to expand our understanding of the inner workings of the critical checkpoint machinery. The present understanding has provided ample appreciation that response to checkpoint activation is manifested through coordinated inhibition of cyclin-dependent kinase (CDK) complexes in G1, S and/or the G2 phase in order to arrest the cell cycle. Kinase inhibition can occur through several mechanisms, including inhibitory phosphorylation of CDK, destruction of the cognate cyclins, and recruitment of CDK inhibitors from the INK and WAF1/CIP1 families. However, the wealth of information from recent discoveries needs to be examined critically to consolidate our conceptual knowledge of checkpoints. At the same time, there is acute awareness in the diversity of checkpoint response between cytotoxic agents, and this serves as a reminder of the magnitude of complexity that is inherent in checkpoint regulation. This volume is intended to bring the cancer research community closer toward an improved understanding of this regulation, how checkpoint abnormalities can impact negatively on cancer therapy, and emerging strategies to target checkpoint response as a therapeutic end-point. Checkpoint regulation is critical in understanding cancer development and cancer therapy. This book builds upon existing concepts of checkpoints and aims to expand our understanding of the inner workings of the critical checkpoint machinery. Buch (fremdspr.) Bücher>Fremdsprachige Bücher>Englische Bücher, Humana Press

Nouveaux livres Thalia.de
No. 30710177 Frais d'envoi, Versandfertig in 2 - 3 Tagen, DE (EUR 0.00)
Details...
(*) Livre non disponible signifie que le livre est actuellement pas disponible à l'une des plates-formes associées nous recherche.
Checkpoint Controls and Targets in Cancer Therapy - Herausgegeben von Siddik, Zahid H.
Livre non disponible
(*)
Herausgegeben von Siddik, Zahid H.:
Checkpoint Controls and Targets in Cancer Therapy - Livres de poche

2012, ISBN: 9781617796357

[ED: Softcover], [PU: Springer, Berlin], Checkpoint regulation is critical in understanding cancer development and cancer therapy. This book builds upon existing concepts of checkpoints and aims to expand our understanding of the inner workings of the critical checkpoint machinery.2012. xiv, 274 S. 30 SW-Abb., 13 Farbabb., 7 Tabellen,. 254 mmVersandfertig in 3-5 Tagen

Nouveaux livres Booklooker.de
buecher.de GmbH & Co. KG
Frais d'envoizzgl. Versandkosten, Livraison non-comprise
Details...
(*) Livre non disponible signifie que le livre est actuellement pas disponible à l'une des plates-formes associées nous recherche.
Checkpoint Controls and Targets in Cancer Therapy - Zahid H. Siddik
Livre non disponible
(*)
Zahid H. Siddik:
Checkpoint Controls and Targets in Cancer Therapy - Livres de poche

2012, ISBN: 9781617796357

ID: 22231205

Softcover, Buch, [PU: Humana Press Inc.]

Nouveaux livres Lehmanns.de
Frais d'envoiVersand in 7-9 Tagen, , Versandkostenfrei innerhalb der BRD (EUR 0.00)
Details...
(*) Livre non disponible signifie que le livre est actuellement pas disponible à l'une des plates-formes associées nous recherche.

< Retour aux résultats de recherche...
Détails sur le livre
Checkpoint Controls and Targets in Cancer Therapy
Auteur:

Zahid H. Siddik

Titre:

Checkpoint Controls and Targets in Cancer Therapy

ISBN:

9781617796357

Informations détaillées sur le livre - Checkpoint Controls and Targets in Cancer Therapy


EAN (ISBN-13): 9781617796357
ISBN (ISBN-10): 1617796352
Livre de poche
Date de parution: 2012
Editeur: Humana Press
288 Pages
Poids: 0,544 kg
Langue: Englisch

Livre dans la base de données depuis 30.07.2008 15:40:12
Livre trouvé récemment le 02.08.2016 12:55:47
ISBN/EAN: 9781617796357

ISBN - Autres types d'écriture:
1-61779-635-2, 978-1-61779-635-7

< Retour aux résultats de recherche...
< pour archiver...
Adjacent Livres